EUVIMEDEUVIMED entdecken
Crossref

Comprehensive pancancer analysis reveals that LPCAT1 is a novel predictive biomarker for prognosis and immunotherapy response

Hongyu Gao, Jinfeng Zhu, Tong Wu, Qian Long, Xinyu Guan, Qitong Chen, Wenjun Yi iD

Apoptosis · 2024

DOI: 10.1007/s10495-024-02010-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, 2024. Verfasst von Hongyu Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: 1-Acylglycerophosphocholine O-Acyltransferase, Biomarkers, Tumor, Immunotherapy, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: The Innovation Platform and Talent Plan of Hunan Province, Beijing Life Oasis Public Service Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a crucial enzyme involved in phospholipid metabolism and is essential for maintaining the structure and functionality of biofilms. However, a comprehensive examination of the role of LPCAT1 across various cancer types is lacking. Multiple public databases have been utilized to examine LPCAT1 expression, genetic alterations, methylation, prognosis, biological function, and its relationship with antitumor immunity in different cancer types. The function of LPCAT1 in glioma, breast cancer and liver cancer cells was further verified using in vitro experiments. Our research indicated that LPCAT1 is upregulated in various cancers and is accompanied by a wide range of amplification mutations. Higher LPCAT1 expression was associated with poorer prognosis across multiple cancers. Further in vitro experiments demonstrated that interfering with LPCAT1 expression increased apoptosis in glioma, breast cancer and liver cancer cells and concurrently suppressed their proliferation and migration. Functional enrichment analysis revealed that LPCAT1-associated genes were primarily enriched in immune and cancer progression pathways, such as the JAK/STAT, MYC, and EMT, etc. Moreover, LPCAT1 expression was closely associated with immune cell infiltration and immune checkpoint-related gene expression. Interestingly, LPCAT1 expression levels were generally higher in patients in the immunotherapy response group. The combination of LPCAT1 and PDL1 serves as an effective predictor of immunotherapy response. In conclusion, LPCAT1 is involved in immune regulation and tumor progression and holds promise as a biomarker for predicting patient outcomes and immunotherapy efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

1-Acylglycerophosphocholine O-AcyltransferaseBiomarkers, TumorImmunotherapyGene Expression Regulation, NeoplasticHumansPrognosisCell Line, TumorCell ProliferationApoptosisFemaleNeoplasmsGliomaBreast NeoplasmsCell Movement

Stichwörter der Autor:innen

BiomarkerImmunotherapyLPCAT1PancancerPrognosis

Substanzen

1-Acylglycerophosphocholine O-AcyltransferaseBiomarkers, TumorLpcat1 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Clinical Research Center For Breast Disease In Hunan Province, Changsha, Hunan, China.
  • Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. yiwenjun@csu.edu.cn.
  • Clinical Research Center For Breast Disease In Hunan Province, Changsha, Hunan, China. yiwenjun@csu.edu.cn.

ORCID-Profile: Wenjun Yi

Förderung

  • The Innovation Platform and Talent Plan of Hunan Province
  • Beijing Life Oasis Public Service Center

Zitieren

APA

Gao, H., Zhu, J., Wu, T., Long, Q., Guan, X., Chen, Q., & Yi, W. (2024). Comprehensive pancancer analysis reveals that LPCAT1 is a novel predictive biomarker for prognosis and immunotherapy response. Apoptosis. https://doi.org/10.1007/s10495-024-02010-y

Vancouver

Gao H, Zhu J, Wu T, Long Q, Guan X, Chen Q, et al. Comprehensive pancancer analysis reveals that LPCAT1 is a novel predictive biomarker for prognosis and immunotherapy response. Apoptosis. 2024. doi:10.1007/s10495-024-02010-y

BibTeX
@article{Gao2024,
  author = {Gao, Hongyu and Zhu, Jinfeng and Wu, Tong and Long, Qian and Guan, Xinyu and Chen, Qitong and Yi, Wenjun},
  title = {Comprehensive pancancer analysis reveals that LPCAT1 is a novel predictive biomarker for prognosis and immunotherapy response},
  journal = {Apoptosis},
  year = {2024},
  doi = {10.1007/s10495-024-02010-y}
}
Kostenlos starten →